A Phase 4 interventional study of Treatment with 137 µg azelastine hydrochloride and 50 μg of fluticasone propionate in Allergic Rhinitis Due to Allergens, sponsored by Viatris Inc.. Completed at 14 sites in China. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Viatris Inc. · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 82 studies in Rhinitis, Allergic with a site in China — 32 open to participants now, 34 under way, 2 of them phase 3. Rhinitis, Allergic · China.
Among the 82 studies in Rhinitis, Allergic with a site in China, this one is the 28th largest by enrollment of the 67 interventional ones that give a count, is one of 7 that started in 2026, is one of 9 in phase 4, and was the 77th registered.
717 studies on the registry are indexed under Rhinitis, Allergic; 94 are open to participants now.
Browse Rhinitis, Allergic studies →32 of the 82 studies in Rhinitis, Allergic with a site in China are open now. Recruiting first, the newest first:
Fujian Mindong Rejuvenation Pharmaceutical Co., Ltd. · Sites in China
Ages 18–65
The Children's Hospital of Zhejiang University School of Medicine · Sites in China
Ages 5–18
Pengfei Qiu · Sites in China
Ages 18–75
Inmunotek S.L. · Sites in China, Argentina, Portugal and 1 more country
Ages 12–65
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–65
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 54 Rhinitis, Allergic studies recruiting now, 11 (20%) set no upper age limit and 38 (70%) stop at 75 or younger; 22 take children under 18; 13 take healthy volunteers.
This study: 12 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
82 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 10 · Phase 3 11 · Phase 4 9
First in 2006; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 100 is above the median of 68 across 552 interventional studies indexed under Rhinitis, Allergic.
Median enrollment 93 across the 67 interventional studies, 270 across the 15 observational. Of the 40 that completed or were terminated, 3 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 82 have an industry lead sponsor. The 10 most frequent:
Viatris Inc. is the lead sponsor of 7 studies on the registry; 5 are open to participants now.
Viatris Inc. has 8 studies filed under Rhinitis, Allergic — fewer than ten, so there is no comparison to draw.
8 of the studies in Rhinitis, Allergic with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07711262Phase 3Fujian Mindong Rejuvenation Pharmaceutical Co., Ltd.Rupatifen Fumarate Capsules in Patients With Seasonal Allergic Rhinitis | 2027-10 |
| NCT07868224Jiangxi University of Traditional Chinese MedicineValidating Blinding Maintenance of a Sham-Sensitization Control Design for Sensitization Acupuncture Trials | 2026-12-01 |
| NCT07784491Zhongshan Torch Development Zone People's HospitalSphenopalatine Ganglion Acupuncture for Allergic Rhinitis | 2026-12-31 |
| NCT07079748LanZhou UniversityStudy of the Effects and Mechanisms of Yeast Postbiotics on Persistent Allergic Rhinitis Symptoms | 2026-12-31 |
| NCT07453771The Affiliated Hospital of Qingdao UniversitySafety and Efficacy of Small Extracellular Vesicles Nebulizer in Patients With Allergic Rhinitis Complicated With Asthma | 2027-02-28 |
Add all 8 to your calendar (.ics) → With an account.
Among the 82 studies in Rhinitis, Allergic with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if the investigational drug product ("study drug"), Dymista (azelastine hydrochloride and fluticasone propionate) nasal spray is safe and effective in the treatment of allergic rhinitis in Chinese adolescents with or without ocular symptoms.
It is expected that approximately, 100 participants will be enrolled in this study. The study will be performed in approximately 15 clinical study centers in China.
Study participants will be asked to complete up to 3 study visits at the study site and a follow-up by telephone.
Treatment Assignment:
All participants will receive a bottle of Dymista nasal spray and should administer it at a dose of twice daily (one spray per nostril), once in the morning and once in the afternoon, the doses will be approximately 12 hours apart. The liquid medicine is sprayed out in a mist after actuator is pressed. You will administer the trial intervention for 14 (+5) days.
Regular study schedule:
Trial Design and Rationale for Trial Design:
This is a multicenter, phase 4, single arm clinical trial to evaluate the efficacy and safety of Dymista nasal spray (137 μg of azelastine hydrochloride and 50 μg of fluticasone propionate) in the treatment of AR in Chinese adolescents with or without ocular symptoms. Because Dymista has already been approved, this trial design is selected to gather additional data on efficacy and safety of Dymista in Chinese adolescents in a close to real-world setting but under clinical oversight.
Number of Participants: Approximately 100 participants will be enrolled into the study.
Number of Arms: Single arm
Duration: Total duration of trial participation for each participant will vary from 29 to 60 days (depending on extended periods of screening, treatment, and follow-up).
This trial starts with approximately -7 to 1 day of screening period, i.e., Visit 2 (start of treatment) can eventually be on the same day of Visit 1 or up to 7 days later. Treatment period will be for 2 weeks (14+5 days) during which participants will administer Dymista nasal spray (137 μg of azelastine hydrochloride and 50 μg of fluticasone propionate) in each nostril, twice daily (BID) and then return to the study site at Visit 3 for end of study examination on Day 15 (+5). Subsequently, participants will be followed up for any AEs for 2 weeks (14+5 days) after the last dose via phone. Once an AE is detected and ongoing, it should be followed up at least two weeks later (i.e., 28 (+5) days after last dose) until its resolution or until it is judged by the principal investigator to be stable or permanent.
Blinding: Not Applicable (No blinding).
Main Selection Criteria - Inclusion and Exclusion criteria of Trial Population:
The Inclusion Criteria for the study focus on enrolling Chinese participants aged 12-17 years who have moderate-to-severe seasonal and/or perennial AR, with or without ocular symptoms. Participants must show signs of Immunoglobulin E (IgE)-mediated hypersensitivity confirmed by diagnostic tests, have acute allergic rhinitis symptoms at inclusion, and be in general good health. They must also be able to use Dymista nasal spray correctly, agree to complete study requirements such as the patient diary, and provide informed consent/assent along with their legal guardians.
The Exclusion Criteria aim to ensure participant safety and study integrity. Individuals with known allergies to Dymista or its components, pregnant or breastfeeding females, or those unable to comply with study requirements are excluded. Additional exclusions include nasal conditions that interfere with drug delivery, recent nasal or sinus surgery, chronic sinusitis, recent use of investigational drugs or certain medications, respiratory infections, asthma (except mild intermittent), and recent immunotherapy. Individuals anticipating significant environmental changes are also excluded.
Trial Treatment:
Dymista nasal spray (137 μg of azelastine hydrochloride and 50 μg of fluticasone propionate, administered twice daily)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants must have moderate-to-severe seasonal and/or perennial AR with or without ocular symptoms, defined as rhinitis with one or more of the following being present:
Presence of Immunoglobulin E (IgE)-mediated to one or more aeroallergens present in the current participant environment, confirmed by a positive response to an established standard diagnostic test at the site within the last year (before treatment start). Accepted diagnostic tests include:
Exclusion Criteria:
Safety concerns:
Lack of suitability for the study:
Medication/Therapy Time Prior to Screening Visit
Administrative reasons:
- Participants anticipating significant changes in their daily environmental exposure (e.g. travel more than 3 days).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study drug will be delivered as an intranasal spray of Dymista (137 μg of azelastine hydrochloride and 50 μg of fluticasone propionate) in each nostril, BID, approximately 12 hours apart at AM and PM. The formulation is a white suspension which contains 120 sprays per bottle. The liquid medicine is sprayed out in a mist after actuator is pressed.
Drug: Treatment with 137 µg azelastine hydrochloride and 50 μg of fluticasone propionate
Treatment with 137 µg azelastine hydrochloride and 50 μg of fluticasone propionate twice daily in each nostril for 14 days
Change from baseline in AM+PM combined reflective Total Nasal Symptom Score (rTNSS).
Least Sqares (LS) mean change from baseline over 14 days (Day 2 to Day 14) in AM+PM combined rTNSS after treatment with Dymista nasal spray regardless of discontinuation for any reason or low compliance (treatment policy strategy). Explanation of rTNSS scale and score: The reflective Total Nasal Symptom Score (TNSS) evaluates nasal symptoms associated with AR. It includes four nasal symptoms: nasal itching, nasal congestion, runny nose (rhinorrhea) and sneezing. The symptom severity is scored on a four-point scale \[0-3\] for each symptom, where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms, and 3 = severe symptoms. The severity of each symptom is assessed to arrive at the total TNSS score, which ranges from 0 to 12. Hence, the AM + PM combined TNSS ranges from 0 to 24.
Time frame: From enrollment to end of treatment at 2 weeks.
Changes from baseline in AM+PM combined reflective TOSS
The secondary objective is to evaluate efficacy in relief of further Allergic Rhinitis (AR) associated symptoms of Dymista in Chinese adolescents, having moderate to severe seasonal and/or perennial AR with or without ocular symptoms. Explanation of TOSS scale and scores: The reflective Total Ocular Symptom Score (TOSS) evaluates ocular symptoms associated with AR. It includes three symptoms: itchy eyes, watery eyes, and eye redness. The symptom severity is scored on a fourpoint scale \[0-3\] for each symptom, where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms, and 3 = severe symptoms. The severity of each symptom is assessed to arrive at the total TOSS score, which ranges from 0 to 9. Hence, the AM + PM combined TOSS ranges from 0 to 18.
Time frame: From enrollment to the end of treatment at 2 weeks.
Changes from baseline in AM+PM combined reflective T7SS
The secondary objective is to evaluate efficacy in relief of further Allergic Rhinitis (AR) associated symptoms of Dymista in Chinese adolescents, having moderate to severe seasonal and/or perennial AR with or without ocular symptoms. Explanation of T7SS scale and scores: The reflective Total 7 Symptom Score (T7SS) evaluates the combined nasal and ocular symptoms (reflective Total Nasal Symptom Score + reflective Total Ocular Symptom Score) associated with AR. It includes all seven symptoms from rTNSS and rTOSS combined: nasal itching, nasal congestion, runny nose (rhinorrhea), sneezing, itchy eyes, watery eyes, and eye redness. The symptom severity is scored on a four-point scale \[0-3\] for each symptom, where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms, and 3 = severe symptoms. The severity of each symptom is assessed to arrive at the total rT7SS score, which ranges from 0 to 21. Hence, the AM + PM combined T7SS ranges from 0 to 42.
Time frame: From enrollment to the end of treatment at 2 weeks.
Changes from baseline in individual nasal symptom scores (itchy nose, nasal congestion, runny nose, sneezing) and ocular symptom scores (itchy eyes, watery eyes, eye redness)
The secondary objective is to evaluate efficacy in relief of further Allergic Rhinitis (AR) associated symptoms of Dymista in Chinese adolescents, having moderate to severe seasonal and/or perennial AR with or without ocular symptoms. The symptom severity is scored on a four-point scale \[0-3\] for each symptom, where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms, and 3 = severe symptoms. Hence, each AM + PM combined individual symptom score ranges from 0 to 6.
Time frame: From enrollment to the end of treatment at 2 weeks.
Number of Subjects With Treatment-emergent Adverse Events (TEAEs)
An adverse event (AE) is any untoward medical occurrence in a participants or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory or physical findings, symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product whether or not considered related to the medicinal product. TEAE is defined as AE with onset date/time since the first dosing of study medication until 120 hours after the last dose of study medication.
Time frame: From enrollment to 14 days after the last dose.
Plan to share: No — Company procedures to share IPD are under development. If procedures are established during the course of the study, the plan will be described.
No publications or documents are linked to this record.
Ran from May 2026 to primary completion in Sep 2026, 4 months.
Of 34 phase 4 interventional studies under Rhinitis, Allergic, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 38. This study's 4 months is below that.
Primary completion moved twice since we started tracking on Sep 25, 2026: Mar 2027 → Sep 2026, last on Nov 3, 2026.
Completion moved once since we started tracking on Sep 25, 2026: Mar 2027 → Oct 2026, on Sep 29, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.